Compare Tango Therapeutics Inc. (TNGX) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.98 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 35.3× Tango Therapeutics Inc.'s market cap, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vanguard Dividend Appreciation Index Fund ETF for 134 Days on average.
| TNGX | VIG | |
|---|---|---|
Market Cap | $3.75B | $132.40B |
Volume | 9,619,106 | 1,027,126 |
Sector | Health | — |
52-Week High | $32.90 | $246.61 |
52-Week Low | $7.50 | $210.70 |
Typical Hold Time | 0 Days | 134 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VIG trades at $239.98, showing minimal daily movement with a slight decline of 0.02%. The technical outlook is bullish based on moving averages, though oscillators are neutral. Recent news highlights its focus on dividend growth, with a 7.5% quarterly dividend increase noted by Seeking Alpha on September 27, 2026. The ETF's strategy excludes high-yield stocks to prioritize consistent dividend growers, as reported by The Motley Fool on September 26, 2026.
The outlook for VIG is supported by its historical average annual returns of 10%, but risks include slow dividend growth and competition from higher-yield ETFs. Investor sentiment is mixed, with some analysts favoring its growth profile over immediate income. Key risks involve market volatility and the ETF's strict eligibility criteria limiting yield potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
